Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Eur J Immunol. Author manuscript; available in PMC Apr 10, 2008.
Published in final edited form as:
PMCID: PMC2291526

CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice


Mechanisms responsible for the development of autoimmune skin disease in humans and animal models with lupus remain poorly understood. In this study, we have investigated the role of CD1d, an antigen-presenting molecule known to activate natural killer T cells, in the development of inflammatory dermatitis in lupus-susceptible MRL-lpr/lpr mice. In particular, we have established MRL-lpr/lpr mice carrying a germ-line deletion of the CD1d genes. We demonstrate that CD1d-deficient MRL-lpr/lpr mice, as compared with wild-type littermates, have more frequent and more severe skin disease, with increased local infiltration with mast cells, lymphocytes and dendritic cells, including Langerhans cells. CD1d-deficient MRL-lpr/lpr mice had increased prevalence of CD4+ T cells in the spleen and liver and of TCRαβ+B220+ cells in lymph nodes. Furthermore, CD1d deficiency was associated with decreased T cell production of type 2 cytokines and increased or unchanged type 1 cytokines. These findings indicate a regulatory role of CD1d in inflammatory dermatitis. Understanding the mechanisms by which CD1d deficiency results in splenic T cell expansion and cytokine alterations, with increased dermal infiltration of dendritic cells and lymphocytes in MRL-lpr/lpr mice, will have implications for the pathogenesis of inflammatory skin diseases.

Keywords: Autoimmunity, CD1d, Dermatitis, Lupus, NKT cells

1 Introduction

MRL-lpr/lpr (MRL-lpr) mice spontaneously develop inflammatory lesions in skin, kidneys and blood vessels, along with marked lymphoproliferation, autoantibody production and hypergammaglobulinemia [16]. These mice have been widely used as a model to study the pathogenesis of SLE, a multi-organ autoimmune disease [7]. Skin lesions that resemble human discoid lupus erythematosus typically develop on the dorsum of the neck, forehead and ears of MRL-lpr mice. Histology of these lesions reveals epidermal hyperplasia, vacuolar cell changes, cellular infiltration and epidermal ulcerations [3, 4]. These lesions markedly worsen in MRL-lpr mice that have been rendered deficient in β2-microglobulin (β2m) [8].β2m-deficient MRL-lpr mice, however, experience mild nephritis and have reduced levels of autoantibodies [810]. While serum IgG1 levels are reduced, IgM, IgG2a and IgG3 levels remain elevated in β2m-deficient MRL- lpr mice [8, 9]. The mechanism(s) by which β2m deficiency differentially regulates the expression of various manifestations of lupus is unclear.

Since β2m is required for the optimal expression of MHC class I and class I-related proteins with which it noncovalently associates, β2m deficiency can affect various molecules such as classical MHC class I, CD1d, Qa-1 and neonatal Fc receptor [11]. One possibility is that different β2m-dependent molecules have different effects on the development of various manifestations of lupus. For example, amelioration of kidney disease in β2m-deficient MRL-lpr mice may be due to deficiency of neonatal Fc receptor [10], which plays a role in the regulation of serum Ig levels [10, 12]. However, decreased Ig levels would not account for the exacerbation of dermatitis in β2m-deficient MRL-lpr mice. Another possibility is that the lack of conventional MHC class I-restricted CD8+ T cells is responsible for the increased skin disease in β2m-deficient MRL-lpr mice. However, CD8-deficient MRL-lpr mice have no increase in skin disease, at least until 16 weeks of age [13]. A third possibility is that a deficiency in regulatory CD1d-dependent natural killer T (NKT) cells is responsible for the increased skin disease in β2m-deficient MRL-lpr mice. In fact, MRL-lpr mice exhibit a selective reduction in the numbers and functions of invariant (Vα14Jα18) NKT cells before the onset of clinical disease [14]. Other studies have also found a specific decrease in the expression of invariant Vα14 TCR mRNA by NKT cells before the onset of disease in MRL-lpr mice [15] and in the numbers of NK1.1-expressing cells in C57BL/6-lpr mice [16]. Consistent with a protective role of CD1d-reactive T cells, patients with SLE also have a selective reduction of NKT cells [1719]. Finally, activation of these cells can reduce autoantibody production and protect against various immune-mediated diseases including type 1 diabetes and experimental autoimmune encephalomyelitis [2026].

The role of NK1.1+ cells, which include NK cells, classical NKT cells and small subsets of other cell types that express this marker, in the development of autoantibodies in C57BL/6-lpr mice has been investigated [16]. These studies showed that: (a) NK1.1+ cells inhibit anti-DNA Ab-secreting cells in vitro; (b) injection of these animals with anti-NK1.1 Ab results in increased numbers of anti-DNA Ab-forming spleen cells ex vivo; and (c) adoptive transfer of C57BL/6-lpr mice with B cell-depleted spleen cells, which contained 30–40% NK1.1+CD3+ cells, 20–30% NK1.1+CD3 cells and 30–50% non-NK/NKT cells, results in delayed appearance of anti-DNA Ab-secreting spleen cells ex vivo [16]. Thus, this report suggests a regulatory role for NK1.1-expressing cells on autoantibody-producing B cells. However, the effect on in vitro anti-DNA Ab-forming cells observed in this study could have been due to either NKT (NK1.1+CD3+) or classical NK (NK1.1+CD3) cells. Moreover, some NKT cells, e.g. most invariant NKT (CD1d-αGalCer tetramer+) cells in MRL-lpr mice, do not express the NK1.1 marker [14]. The latter CD1d-reactive T cells would not have been depleted by treatment with anti-NK1.1 Ab. Finally, this study did not report on any clinical manifestations of lupus disease.

NKT cells recognize glycolipid antigens in the context of the non-classical MHC class I molecule CD1d [27]. Two closely related genes, CD1d1 and CD1d2, share 95% sequence homology and encode mouse CD1 [28]. CD1d1 is widely expressed on B and T cells, macrophages and dendritic cells [29, 30], whereas CD1d2 is detected mainly on thymocytes and is considered nonfunctional [30].

We generated CD1d-deficient MRL-lpr mice by crossing the CD1d1- or CD1d1d2-null genotypes [31, 32] onto the MRL-lpr background and evaluated the effects of CD1d deficiency on the development of inflammatory dermatitis. Our results demonstrate that CD1d deficiency exacerbates the frequency and severity of skin lesions in MRL-lpr mice.

2 Results

2.1 CD1d deficiency exacerbates inflammatory skin lesions in MRL-lpr mice

To investigate the role of CD1d in the development of lupus-like disease, we generated CD1d knockout (KO) MRL-lpr mice by crossing the CD1d1-null genotype from the stock C57BL6/Sv129 mice [31] onto the MRL-lpr background. The final CD1d1 KO MRL-lpr mice and their wild-type (WT) littermates were monitored for the development of skin, kidney and lymphoproliferative disease, and their sera were tested for autoantibodies.

MRL-lpr mice develop inflammatory skin lesions that typically manifest as hair loss and scab formation on the dorsal neck region as well as cellular infiltration and epidermal hyperplasia visible on histology [3, 4]. We monitored the development of such skin lesions and scored the skin biopsy sections from dorsal regions of the neck for cellular infiltration, epidermal hyperplasia and epidermal ulcerations. As shown in Fig. 1A and 1B, the cumulative frequency of skin lesions and composite skin biopsy scores were increased in CD1d1 KO mice as compared to WT mice. Five of 11 (45%) WT mice had a minimal (0.5) to mild (1+) inflammation, and epidermal hyperplasia or focal ulcerations were detectable in two separate mice, whereas 7 of 9 (77%) CD1d1 KO mice had a moderate (2+) to mild (1+) cellular infiltration and epidermal hyperplasia, with multifocal ulcerations in 2 of these mice (Fig. 1B). Whereas 16-week-old WT MRL-lpr mice had a minimal infiltration with neutrophils, mast cells and lymphocytes, the CD1d1 KO littermates had an intense infiltration with mast cells, neutrophils and lymphocytes (Fig. 1C). Most infiltrating lymphocytes in both WT and KO mice were CD3+ T cells, as determined by immunohistochemistry (data not shown). Skin sections from the KO animals also exhibited other features of chronic cutaneous lupus, such as vacuolar cells in the basal layers of epidermis and fibroplasia in the dermis (Fig. 1C).

Fig. 1
Skin manifestations of lupus in 16-week-old CD1d-deficient MRL-lpr mice. (A) Cumulative frequency of skin lesions. Skin lesions were scored on a scale of 0–3 (see Methods; p<0.05). (B) A composite skin biopsy score (see Sect. 4) is expressed ...

Activated dendritic cells, such as Langerhans cells, infiltrate the skin during the active stages of spontaneous skin lesions in humans with SLE and in MRL-lpr mice [3, 33]. To investigate if exacerbation of skin disease in CD1d KO mice is associated with an expansion of these cell types, we performed immunohistochemistry to detect resident skin dendritic cells (Fig. 1D, E). Although occasional cells in the epidermis of WT mice expressed S100 antigen [34] and displayed the morphology of Langerhans cells, these cells were clearly increased in the dermis of CD1d KO mice (Fig. 1D). However, not all S100-expressing cells had the morphology of Langerhans cells, and the S100 antigen is known to be expressed by melanocytes, adnexal glands and Schwann cells of the skin [34]. We therefore stained skin sections with anti-CD11c; a marked increase in CD11c-expressing cells was found in KO animals as compared to WT littermates (Fig. 1E). Thus, CD1d KO MRL-lpr mice exhibit a significant expansion of skin dendritic cells.

MRL-lpr mice also develop nephritis [6] and autoantibodies to nuclear antigens [1, 2]. We found that renal histological changes, severe proteinuria, serum anti-DNA Ab levels and total serum IgM, IgE, IgG1, IgG2a, IgG2b and IgG3 levels were not significantly different between CD1d KO and WT littermates (Fig. 2 and data not shown).

Fig. 2
Renal histological changes in CD1d KO MRL-lpr mice and WT littermates. Composite kidney biopsy scores (KBS) in 3-month-old female (A), 5–6-month-old female (B) and 6–7-month-old male (C) mice are shown as the mean scores ± SE ( ...

In the absence of the CD1d1 gene, the second murine CD1d gene, CD1d2, might partially or completely compensate for the genetic deficiency of CD1d1. To address this possibility, we crossed the CD1d1/d2-null [32] genotype onto the MRL-lpr background and examined the resulting KO mice for the above-mentioned parameters of lupus at 3–4 and 5–7 months of age. The results in the double KO mice essentially corroborated the findings obtained with the single KO MRL-lpr mice.

2.2 Increased prevalence of CD4+ and TCRαβ+B220+ cells in CD1d KO MRL-lpr mice

MRL-lpr mice develop enlargement of lymphoid organs, with accumulation of conventional T cells and an abnormal cell population, double-negative TCRαβ+B220+ cells [1, 2]. To address the effect of CD1d deficiency on these manifestations, we examined the extent of organomegaly and cellularity as well as the surface phenotypes of lymphocytes in various lymphoid tissues by flow cytometry (Fig. 3, ,4).4). While the overall cellularity and organ weights in WT and KO mice were similar (Fig. 3), the TCRαβ+B220+ cell population was significantly increased (Fig 4A), whereas the percentage of B cells was decreased (Fig. 4B), in the lymph nodes of 3-month-old CD1d KO MRL-lpr mice. In the spleens and livers of CD1d KO mice, CD4+ T cells were significantly increased as compared to WT littermates (Fig. 4B). The absolute cell numbers also showed a similar trend, although the differences did not reach statistical significance. No significant differences in lymphocyte phenotypes were observed in older (6 months) KO mice vs. WT littermates (data not shown).

Fig. 3
Lymphoproliferative manifestations of lupus in CD1d-deficient MRL-lpr mice. Organ weights and cellularity of thymus (A), liver (B) and spleen, axillary lymph nodes (ALN) and mesenteric lymph nodes (MLN) (C) are shown as the mean ± SE in CD1d-deficient ...
Fig. 4
Surface phenotype of lymphocytes in 3-month-old CD1d KO and WT MRL-lpr mice. The percentages of double-negative TCRαβ+B220+ (A), CD4+, CD8+ or B220+ (B) cells are shown as the mean ± SE (*p<0.05; n=16 mice/group). LN: lymph ...

2.3 Decreased type 2 cytokines (IL-4 and IL-10) in CD1d KO MRL-lpr mice

Abnormalities in cytokine production have been suggested to contribute to the development of disease in MRL-lpr mice [35]. Since repeated activation of CD1d-reactive NKT cells can alter the overall cytokine balance towards a type 2 cytokine profile in MRL-lpr mice [14], the lack of such cells in CD1d KO mice may result in decreased type 2 and/or increased type 1 immune responses. Indeed, while the production of the type 1 cytokine IFN-γ by Con A-stimulated splenic T cells was slightly increased, the type 2 cytokines IL-4 and IL-10 were significantly decreased in CD1d KO mice as compared to WT animals (Fig. 5).

Fig. 5
Effect of CD1d deficiency on T cell cytokine secretion in MRL mice. Spleen cells from CD1d KO mice and WT littermates were stimulated with Con A for 2 days. Culture supernatants were tested for cytokines. Results are expressed as the mean values ± ...

3 Discussion

Our results indicate that CD1d deficiency exacerbates inflammatory skin disease in MRL-lpr mice. To explore the mechanisms by which CD1d deficiency may affect the development and course of inflammatory skin disease, we investigated its effect on lymphocyte populations and their cytokine responses. CD4+ T cells were consistently increased in the spleens of CD1d KO MRL-lpr mice, and CD3+ T cells infiltrated their skin (Fig. 4B and data not shown). Such T cell expansion may contribute to disease exacerbation, as TCRαβ+ cells are essential for the development of disease in MRL-lpr mice [36]. Furthermore, upon T cell stimulation, spleen cells from CD1d KO MRL-lpr mice produced lower levels of the immunoregulatory cytokines IL-4 and IL-10 than the WT littermates (Fig. 5), which could be responsible for skin disease exacerbation in CD1d KO mice. In fact, a recent study described significant acceleration of skin disease in IL-10 KO MRL-lpr mice [37]. IL-10 also plays a critical role in the development of immune tolerance [38]. Thus, IL-10 produced by CD1d-reactive NKT cells may play a role in the development of immune tolerance that can be facilitated by CD1d-reactive NKT cells [39]. It remains to be determined whether loss of this mechanism results in the activation of autoreactive T cells and exacerbation of autoimmunity in CD1d-deficient MRL-lpr mice. Future experiments are also needed to determine whether imbalances in type 1 versus type 2 cytokines or a reduction in regulatory cytokines or the regulatory T cells that secrete such cytokines result in the expansion of effector CD4+ T cells that infiltrate target organs such as skin.

There is evidence of significant cross-talk between CD1d-reactive T cells and dendritic cells [40, 41], resulting in alterations in the differentiation/maturation of dendritic cell subsets, which may contribute to modulation of auto-immune responses [22]. CD40/CD40L interactions may play an important role in this cross-talk [41]. In this regard, we found that skin dendritic cells including Langerhans cells, which are known to infiltrate the dermis during the active stages of spontaneous skin lesions in SLE [3, 33], were significantly increased in CD1d KO MRL-lpr mice (Fig. 1D, E). Our preliminary studies suggest that the expression of CD40 as well as CD40L, as detected by immunohistochemistry, is also increased in skin sections from CD1d KO MRL-lpr mice as compared to WT littermates (data not shown). Ongoing studies will examine whether deficiency in CD1d and CD1d-reactive T cells affects dendritic cell infiltration, which then contributes to local infiltration with activated T cells and inflammation in target organs such as skin. Alternatively, dendritic cell infiltration may be an indirect effect of inflammation.

An intriguing finding of our study is that CD1d deficiency exacerbates skin disease but does not seem to affect circulating levels of autoantibodies or renal disease. These data suggest that different regulatory mechanisms might account for the various manifestations of lupus. The regulatory effect of CD1d-restricted events may be critical in controlling the local inflammation in the skin but dispensable for the regulation of nephritis. It is possible, however, that the time point that we chose for the detection of skin disease may not be optimal for the detection of renal pathology, as MRL-lpr mice develop renal disease before the onset of skin disease. Nevertheless, proteinuria and renal histological changes were not significantly different in the KO and WT littermates in two separate cohorts. A similar differential regulation of lupus skin vs. renal disease was also observed in β2m-deficient MRL-lpr mice, which had worsened skin lesions, whereas nephritis was ameliorated [8]. In that study, however, CD1d-deficient and CD1d-sufficient MRL-lpr mice had similar incidences of skin and renal disease. The discrepancy between that study and ours could arise from variability in the expression of skin disease in various animal colonies and cohorts. For example, in the previous study [8], the age at which 50% of the WT MRL-lpr mice developed skin disease was 18 weeks in the CD1d cohort and 31 weeks in the β2m cohort, whereas in our animal colony, skin disease appears at approximately 28 weeks (data not shown). Different strategies used to generate the KO mice could also affect the CD1d KO phenotype. In the previous study [8], data obtained from N6 and N10 CD1d KO MRL-lpr mice were pooled, whereas we analyzed data in separate cohorts of N8 or N7 CD1d KO MRL-lpr mice. The N6 to N10 backcrossed mice are expected to carry approximately 0.1–2% founder 129/B6 genes, which may affect the phenotype of CD1d KO MRL-lpr mice. Although our genotype analyses of congenic strains using simple sequence repeat markers centered on most known lupus-suppressor or -susceptibility loci does not suggest a replacement with donor genes at these loci (data not shown), we cannot rule out the possibility that observed effects of the KO reflect the introduction of an adjacent gene cotransferred during the backcross of the mutated 129 locus onto the MRL-lpr genetic background.

In contrast to the lack of an effect of CD1d deficiency on the development of nephritis in MRL-lpr mice, pristane-injected CD1d KO BALB/c mice develop more severe lupus-like nephritis than their WT littermates [26]. Lupus-prone NZB/NZW F1 mice, when rendered deficient in CD1d, also experience an exacerbation of lupus nephritis (manuscript in preparation). In addition, old (>1.5 years) CD1d-deficient BALB/c mice have increased serum anti-DNA Ab levels as compared to age-matched controls (S. Porcelli, personal communication). More direct evidence for the involvement of CD1d-reactive NKT cells in regulation of lupus-like autoimmunity comes from aging B6 Jα18 KO mice, which have elevated anti-DNA and anti-cardiolipin Ab and renal IgG and complement deposition as compared to age-matched B6 controls (S. Porcelli, F. Dieli and G. Sireci, personal communication). It is therefore possible that the regulatory effect of CD1d-restricted events on nephritis require intact Fas signaling, which is absent in MRL-lpr mice, or that the anti-apoptotic effects of mutant Fas ligand are capable of bypassing the role of CD1d-reactive T cells.

In a previous study, adoptive transfer of NK1.1-enriched (NK1.1+CD3+ and NK1.1+CD3) cells reduced the number of CD3+B220+ cells in C57BL/6-lpr mice [16]. This regulatory effect of NK1.1-expressing cells is probably conferred by CD1d-reactive NKT cells, since CD1d KO MRL-lpr mice have an increased TCRαβ+B220+ cell population (Fig. 4A). However, the CD1d deficiency per se does not appear to directly cause the expansion of this cell population, as the numbers of TCRαβ+B220+ cells were comparable in the peripheral lymphoid tissues of normal B6 and CD1d−/− B6 mice (our unpublished data). Furthermore, whereas up-regulation of CD1d on dendritic cells has been found to lead to excessive negative selection of NKT cells [42], it appears to have no effect on the conventional CD8 and CD4 compartments or on TCRαβ+B220+ cells [43]. The levels of CD1d expression on dendritic cells and thymocytes in MRL-lpr mice are also comparable to those of B6 mice (our unpublished data). Thus, it is unlikely that the abnormal accumulation of CD4CD8TCRαβ+B220+ cells seen in MRL-lpr mice occurs as a consequence of abnormal CD1d-mediated positive and/or negative selection in the thymus. However, we cannot completely exclude the possibility that increased accumulation of this unusual population in CD1d KO MRL-lpr mice occurs as a result of CD1d deficiency influencing central vs. peripheral tolerance.

In conclusion, CD1d appears to play a protective role in the development of lupus dermatitis. Indeed, treatment with α-galactosylceramide, which results in the expansion and activation of CD1d-reactive NKT cells, alleviates dermatitis in MRL-lpr mice [14]. Humans with SLE and other systemic autoimmune diseases also have reduced numbers of NKT cells, and disease activity in patients with SLE appears to inversely correlate with circulating NKT cell numbers [1719]. Understanding the mechanisms by which CD1d-restricted events regulate the development of lupus dermatitis in animal models and subsets of lupus patients should prove invaluable.

4 Materials and methods

4.1 Animals

Stock MRL-lpr mice were purchased from the Jackson Laboratory (Bar Harbor, ME). To generate CD1d-deficient MRL-lpr mice, CD1d1-null [31] or CD1d1/d2-null [32] stock mice were crossed onto the MRL-lpr background for eight and seven generations, respectively. The CD1d-null genotypes were identified by Southern blotting [31] or PCR [26]. The CD1d KO phenotype was further confirmed by flow cytometry of peripheral blood cells stained with a conjugated anti-CD1d mAb (1B1; PharMingen, San Diego, CA). Mice at the final backcross were screened to confirm that they were indeed congenic for the disease-associated simple sequence repeat markers (including D2Mit324, D3Mit42, D3Mit137, D4Mit12, D4Mit89, D4Mit125, D4Mit147, D4Mit338, D5Mit356, D7Mit211, D10Mit11 and H2-Aa1 [44]; www.informatics.jax.org). All but one of the polymorphic markers discriminated the congenic MRL-lpr mice from the B6 or 129 strains. One of the 12 primer sets discriminated the 129 strain from only 70% of the congenic MRL-lpr mice; however, the 129 marker was equally distributed among the WT and KO littermates in the congenic mice.

4.2 Assessment of skin disease

Inflammatory skin lesions on the forehead, ears and dorsum of the neck [3, 4, 14] were scored on a scale of 0–3, where 0= no visible skin changes, 1= minimal hair loss with redness and a few scattered lesions, 2= redness, scabbing and hair loss with a small area of involvement and 3= ulcerations with an extensive area of involvement. For histology, skin biopsies from the back of neck were stored in 4% paraformaldehyde and sectioned. The hematoxylin and eosin (H&E)-stained sections were independently scored by a pathologist (Greg Boivin) and two of the authors (R.R.S. and J.Y.) for cellular infiltration (score 0–3), epidermal hyperplasia (0–2) and epidermal ulcerations (0–2). Results are expressed as an average of total scores from all readers.

4.3 Skin immunohistochemistry

Frozen sections of skin biopsies were fixed in acetone for 5 min, followed by washing, blocking and incubation with hamster anti-mouse CD11c and CD40L (e-Bioscience, San Diego, CA), hamster anti-CD3 (BD PharMingen), rabbit anti-mouse CD40 (Santa Cruz Biotechnology, Santa Cruz, CA) or isotype control IgG. After washing, sections were incubated with biotinylated goat anti-hamster IgG (e-Bioscience) or anti-rabbit IgG (Vector Lab, Burlingame, CA) and then stained using the Vectastain® ABC-AP kit and Vector® red alkaline phosphatase substrate kit I (Vector Lab) following the manufacturer’s instructions. Staining for S-100 antigen was performed on paraffin sections using a rabbit polyclonal anti-S100 Ab with predominantly beta subunit specificity and the CONFIRM detection kit (Ventana, Tucson, AZ) following the manufacturer’s instructions.

4.4 Assessment of renal disease

Proteinuria was measured using a colorimetric assay strip for albumin (Albustix, Bayer Co., Elkhart, IN), as described [45]. For renal histology, paraffin sections were stained with H&E, periodic acid-Schiff and Masson’s trichrome. Stained sections were scored for the glomerular, tubulointerstitial and vascular lesions, as described [6]. The mean scores were summed to determine a composite kidney biopsy score.

4.5 Flow cytometry

Single cell suspensions from spleen and mesenteric and axillary lymph nodes were prepared by mechanical disruption in complete RPMI medium. Lymphocytes from perfused liver were isolated according to the method described by Goossens et al. [46]. Red blood cells were removed by hypotonic lysis. Cells were stained with FITC-conjugated mAb specific for CD4 (RM4–5) and TCR (H57–597); PE-conjugated mAb specific for CD8α(53–6.7) and B220 (RA3–6B2); and CyChrome-conjugated mAb specific for CD3 (145–2C11) and TCRβ(H57–597). All mAb were purchased from PharMingen. Stained cells (106) were analyzed with a Becton Dickinson (Mountain View, CA) FACSCalibur flow cytometer using CellQuest software. Absolute cell numbers of each cell subset were calculated by the percentage of staining cells × total cell number.

4.6 Detection of autoantibodies and Ig isotypes

IgG anti-dsDNA Ab was measured by ELISA, as described [45]. Rheumatoid factor (Ig κ chain anti-IgG2aa) was determined by ELISA, as described previously [47]. Sera from normal BALB/c mice were used as negative controls. Total serum Ig and its isotypes were measured by a standard sandwich ELISA using the appropriate Ab pairs (Southern Biotechnology).

4.7 Detection of cytokines by ELISA

Splenocytes (1×106–2×106/ml) were stimulated with Con A (1–5 μg/ml) or plate-bound anti-CD3 mAb (1–10 μg/ml) for 48 h. The supernatants were tested for cytokines by ELISA using mAb pairs and recombinant cytokine standards from PharMingen, as described [38].

4.8 Statistical analysis

Levels of Ab and cytokines, lymphocyte percentages and numbers, and renal scores were compared using Graphpad InState software (San Diego, CA). The Student’s t-test was used if the data followed a normal distribution; otherwise, a Mann-Whitney U-test was used. Frequencies of Ab and proteinuria were compared using the two-sided Fisher’s exact test.


We thank Mark Shlomchik for providing reagents for the rheumatoid factor assay, Dwight Kono for suggestions on genotyping the congenic strains, Gregory Boivin and Diya Mutasim for suggestions on skin histology and immunohistochemistry, and Jonathan Jacinto and Tam Bui for the animal care and genotyping. This work was supported in part by grants from the National Institutes of Health (AR47322, AR50797 and DK69282 to R. R. S., AI43407 to C.-R. W. and HL68744 to L. V. K.).


Natural killer T cell


The first two authors contributed equally to the work.


1. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol. 1991;9:243–269. [PubMed]
2. Theofilopoulos AN, Kofler R, Singer PA, Dixon FJ. Molecular genetics of murine lupus models. Adv Immunol. 1989;46:61–109. [PubMed]
3. Kanauchi H, Furukawa F, Imamura S. Characterization of cutaneous infiltrates in MRL/lpr mice monitored from onset to the full development of lupus erythematosus-like skin lesions. J Invest Dermatol. 1991;96:478–483. [PubMed]
4. Furukawa F, Tanaka H, Sekita K, Nakamura T, Horiguchi Y, Hamashima Y. Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res. 1984;276:186–194. [PubMed]
5. Nose M, Nishihara M, Fujii H. Genetic basis of the complex pathological manifestations of collagen disease: lessons from MRL/lpr and related mouse models. Int Rev Immunol. 2000;19:473–498. [PubMed]
6. Singh RR, Saxena V, Zang S, Li L, Finkelman FD, Witte DP, Jacob CO. Differential contribution of IL-4 and STAT6 versus STAT4 to the development of lupus nephritis. J Immunol. 2003;170:4818–4825. [PMC free article] [PubMed]
7. Mills JA. Systemic lupus erythematosus. N Engl J Med. 1994;330:1871–1879. [PubMed]
8. Chan OT, Paliwal V, McNiff JM, Park SH, Bendelac A, Shlomchik MJ. Deficiency in β2-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Faslpr mice: an example of disease regulation at the organ level. J Immunol. 2001;167:2985–2990. [PubMed]
9. Christianson GJ, Blankenburg RL, Duffy TM, Panka D, Roths JB, Marshak-Rothstein A, Roopenian DC. β2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice. J Immunol. 1996;156:4932–4939. [PubMed]
10. Christianson GJ, Brooks W, Vekasi S, Manolfi EA, Niles J, Roopenian SL, Roths JB, Rothlein R, Roopenian DC. β2-microglobulin-deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism. J Immunol. 1997;159:4781–4792. [PubMed]
11. Blumberg RS, van de Wal Y, Claypool S, Corazza N, Dickinson B, Nieuwenhuis E, Pitman R, Spiekermann G, Zhu X, Colgan S, Lencer WI. The multiple roles of major histocompatibility complex class-I-like molecules in mucosal immune function. Acta Odontol Scand. 2001;59:139–144. [PMC free article] [PubMed]
12. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in β2-microglobulin-deficient mice. Eur J Immunol. 1996;26:690–696. [PubMed]
13. Koh DR, Ho A, Rahemtulla A, Fung-Leung WP, Griesser H, Mak TW. Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur J Immunol. 1995;25:2558–2562. [PubMed]
14. Yang JQ, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR. Repeated α-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol. 2003;171:4439–4446. [PubMed]
15. Mieza MA, Itoh T, Cui JQ, Makino Y, Kawano T, Tsuchida K, Koike T, Shirai T, Yagita H, Matsuzawa A, Koseki H, Taniguchi M. Selective reduction of Vα14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol. 1996;156:4035–4040. [PubMed]
16. Takeda K, Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med. 1993;177:155–164. [PMC free article] [PubMed]
17. Oishi Y, Sumida T, Sakamoto A, Kita Y, Kurasawa K, Nawata Y, Takabayashi K, Takahashi H, Yoshida S, Taniguchi M, Saito Y, Iwamoto I. Selective reduction and recovery of invariant Vα24JαQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:275–283. [PubMed]
18. van der Vliet HJ, von Blomberg ME, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, Polman CH, Rustemeyer T, Lips P, van den Eertwegh AJ, Giaccone G, Scheper RJ, Pinedo HM. Circulating Vα24+ Vβ11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol. 2001;100:144–148. [PubMed]
19. Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum. 2001;44:1127–1138. [PubMed]
20. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko O, Miura T, Haba T, Scherer DC, Wei J, Kronenberg M, Koezuka Y, Van Kaer L. The natural killer T cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med. 2001;7:1052–1056. [PubMed]
21. Wang B, Geng YB, Wang CR. CD1-restricted NK T Cells protect nonobese diabetic mice from developing diabetes. J Exp Med. 2001;194:313–319. [PMC free article] [PubMed]
22. Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y, Balk SB, Strominger JL, Clare-Salzer M, Wilson SB. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci USA. 2001;98:13838–13843. [PMC free article] [PubMed]
23. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 2001;413:531–534. [PubMed]
24. Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van Kaer L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med. 2000;194:1801–1811. [PMC free article] [PubMed]
25. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-De-Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi M, Lepault F, Lehuen A, Bach JF, Herbelin A. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med. 2001;7:1057–1062. [PubMed]
26. Yang JQ, Singh AK, Wilson MT, Satoh M, Stanic AK, Park JJ, Hong S, Gadola SD, Mizutani A, Kakumanu SR, Reeves WH, Cerundolo V, Joyce S, Van Kaer L, Singh RR. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol. 2003;171:2142–2153. [PubMed]
27. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol. 1997;15:535–562. [PubMed]
28. Porcelli SA. The CD1 family: a third lineage of antigen-presenting molecules. Adv Immunol. 1995;59:1–98. [PubMed]
29. Brossay L, Jullien D, Cardell S, Sydora B, Burdin N, Modlin RL, Kronenberg M. Mouse CD1 is mainly expressed on hemopoietic-derived cells. J Immunol. 1997;159:1216–1224. [PubMed]
30. Chen YH, Wang B, Chun T, Zhao L, Cardell S, Behar SM, Brenner MB, Wang CR. Expression of CD1d2 on thymocytes is not sufficient for the development of NK T cells in CD1d1-deficient mice. J Immunol. 1999;162:4560–4566. [PubMed]
31. Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity. 1997;6:469–477. [PubMed]
32. Chen YH, Chiu NM, Mandal M, Wang N, Wang CR. Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Immunity. 1997;6:459–467. [PubMed]
33. Kanauchi H, Furukawa F, Imamura S. Evaluation of ATPase-positive Langerhans’ cells in skin lesions of lupus erythematosus and experimentally induced inflammations. Arch Dermatol Res. 1989;281:327–332. [PubMed]
34. Rowden G, Boudreau S, Higley H. Langerhans cells and extra-epidermal dendritic cells. An investigation in laboratory animals and man with immunomorphological methods. Scand J Immunol. 1985;21:471–478. [PubMed]
35. Fitzpatrick JM, Koh JS, Hartwell D, Beller DI, Levine JS. Dysregulated cytokine expression in vivo in prediseased and diseased autoimmune-prone MRL mice. Autoimmunity. 1996;23:217–229. [PubMed]
36. Peng SL, McNiff JM, Madaio MP, Ma J, Owen MJ, Flavell RA, Hayday AC, Craft J. αβ T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J Immunol. 1997;158:2464–2470. [PubMed]
37. Yin Z, Bahtiyar G, Zhang N, Liu L, Zhu P, Robert ME, McNiff J, Madaio MP, Craft J. IL-10 regulates murine lupus. J Immunol. 2002;169:2148–2155. [PubMed]
38. Singh RR, Hahn BH, Sercarz EE. Neonatal peptide exposure can prime T cells, and upon subsequent immunization induce their immune deviation: Implications for antibody- vs. T cell-mediated autoimmunity. J Exp Med. 1996;183:1613–1622. [PMC free article] [PubMed]
39. Sonoda KH, Exley M, Snapper S, Balk SP, Stein-Streilein J. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med. 1999;190:1215–1225. [PMC free article] [PubMed]
40. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003;171:5140–5147. [PubMed]
41. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 1999;189:1121–1128. [PMC free article] [PubMed]
42. Chun T, Page MJ, Gapin L, Matsuda JL, Xu H, Nguyen H, Kang HS, Stanic AK, Joyce S, Koltun WA, Chorney MJ, Kronenberg M, Wang CR. CD1d-expressing dendritic cells but not thymic epithelial cells can mediate negative selection of NKT cells. J Exp Med. 2003;197:907–918. [PMC free article] [PubMed]
43. Xu H, Chun T, Colmone A, Nguyen H, Wang CR. Expression of CD1d under the control of a MHC class Ia promoter skews the development of NKT cells, but not CD8+ T cells. J Immunol. 2003;171:4105–4112. [PubMed]
44. Vidal S, Kono DH, Theofilopoulos AN. Loci predisposing to autoimmunity in MRL-Faslpr and C57BL/6-Faslpr mice. J Clin Invest. 1998;101:696–702. [PMC free article] [PubMed]
45. Fan GC, Singh RR. Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J Exp Med. 2002;196:731–741. [PMC free article] [PubMed]
46. Goossens PL, Jouin H, Marchal G, Milon G. Isolation and flow cytometric analysis of the free lymphomyeloid cells present in murine liver. J Immunol Methods. 1990;132:137–144. [PubMed]
47. Wang H, Shlomchik MJ. Maternal Ig mediates neonatal tolerance in rheumatoid factor transgenic mice but tolerance breaks down in adult mice. J Immunol. 1998;160:2263–2271. [PubMed]
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...